Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(E)-(4S,6S)-6-((S)-2-{(S)-2-[(furan-2-carbonyl)-amino]-3-methyl-butyrylamino}-3-methyl-butyrylamino)-8-methyl-5-oxo-4-((R)-2-oxo-pyrrolidin-3-ylmethyl)-non-2-enoic acid ethyl ester
- Development stage
- Unknown
- Modality
- Peptides, Small Molecules
01
Overview
This compound is a synthetic small molecule with the molecular formula C32H49N5O8 and a molecular weight of approximately 631.8 g/mol[1][2]. It is listed in chemical and drug databases as an experimental agent but does not have an established clinical use or well-documented mechanism of action in humans[1][2]. The structure contains peptide-like bonds and features such as a furan ring, pyrrolidine moiety, and multiple amide linkages. There is no evidence it has reached advanced clinical development or approval for any indication.
- Other names
- (E)-(4S,6S)-6-((S)-2-{(S)-2-[(furan-2-carbonyl)-amino]-3-methyl-butyrylamino}-3-methyl-butyrylamino)-8-methyl-5-oxo-4-((R)-2-oxo-pyrrolidin‑3‑ylmethyl)‑non‑2‑enoic acid ethyl ester
Beyond the preview
Go deeper on (E)-(4S,6S)-6-((S)-2-{(S)-2-[(furan-2-carbonyl)-amino]-3-methyl-butyrylamino}-3-methyl-butyrylamino)-8-methyl-5-oxo-4-((R)-2-oxo-pyrrolidin-3-ylmethyl)-non-2-enoic acid ethyl ester.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (E)-(4S,6S)-6-((S)-2-{(S)-2-[(furan-2-carbonyl)-amino]-3-methyl-butyrylamino}-3-methyl-butyrylamino)-8-methyl-5-oxo-4-((R)-2-oxo-pyrrolidin-3-ylmethyl)-non-2-enoic acid ethyl ester.